SPECIAL CENTRE FOR MOLECULAR MEDICINE
JAWAHARLAL NEHRU UNIVERSITY
a seminar on
Discovery towards the next generation of antimalarials
by
Dr. Jeremy N. Burrows
Vice President, Head of Drug Discovery
Medicines for Malaria Venture
Geneva, Switzerland
6th December 2017, Time: 11.00 am
Seminar Room, SCMM, JNU, New Delhi
Dr. Jeremy N. Burrows is the Vice President and leads the MMV’s Drug Discovery team. Trained as a synthetic organic chemist with Jeremy Robertson at Oxford University and he received his D.Phil. in 1996. Since then he worked at AstraZeneca until 2008 as a medicinal chemist working in areas of rheumatoid and osteoarthritis, diabetes, neurology and anti-infectives and finally joined MMV.
Abstract: Malaria is a devastating disease affecting millions of people each year yet, surprisingly, apart from the Artemisinin Combination Therapies (ACTs) there are relatively few effective treatments for Plasmodium falciparum and only one complete treatment for Plasmodium vivax. MMV manages a significant antimalarial pipeline and this has been strengthened in recent years with the delivery of new products, new clinical candidates and early stage discovery projects. The talk will explain both the challenges that need to be overcome and the strategy adopted to control and eradicate the disease, including definitions of target product and candidate profiles necessary for asexual blood stage cures (including single dose combination treatment), transmission blocking, vivax and chemoprotection. Tactics involving phenotypic and target based screening will also be described as well as case studies of successful candidates discovered using the different approaches.
All are welcome